← Leaderboards
Neelima B Chauhan
University Of Illinois At Chicago
$1,494,977
Attributed
$1,494,977
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $342.9K · FY2005–16$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,494,977 · 4
VA$0 · 1
By mechanism
R21$1,494,977 · 4
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Djaja D Soejarto$1,000,284
- Haohua Qian$2,072,624
- David R Pepperberg$10,873,202
- Harris Ripps$2,311,002
- Holly E Johnson$57,645
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelCognitive DeficitsBiochemicalAnatomyAxonStagingPhysiologicalDrug CandidateMono-SSynapsesReportingTreatment EfficacyFunctional DisorderMemoryLearningNeuronsCognitionApoptosisComplexBrainAfghanistanBrain ConcussionAmericanAfferent Neurons
Grant awards (13)
Neuroregenerative Effects of Simvastatin in TBI$0
I01 · FY2016 · VA · contact PI
Neuroregenerative Effects of Simvastatin in TBI$0
I01 · FY2015 · VA · contact PI
Neuroregenerative Effects of Simvastatin in TBI$0
I01 · FY2015 · VA · contact PI
Neuroregenerative Effects of Simvastatin in TBI$0
I01 · FY2015 · VA · contact PI
Therapeutic Efficacy of Intranasal WGA-GLP1 in AD$197,381
R21 · FY2014 · NS · contact PI
Therapeutic Efficacy of Intranasal WGA-GLP1 in AD$239,250
R21 · FY2013 · NS · contact PI
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD$133,875
R21 · FY2012 · AG · contact PI
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD$77,991
R21 · FY2012 · AG · contact PI
WGA as a Novel Vehicle for Intranasal Delivery of an Anti-A-beta Antibody in AD$160,650
R21 · FY2011 · AG · contact PI
Determining Therapeutic Efficacy of AGE in AD$194,838
R21 · FY2005 · AT
Reduction of Amyloid Burden by Antisense APP$148,077
R21 · FY2005 · NS
Determining Therapeutic Efficacy of AGE in AD$194,838
R21 · FY2004 · AT
Reduction of Amyloid Burden by Antisense APP$148,077
R21 · FY2004 · NS